Nektar wins $90M Lilly jury verdict, but cash is still contingent

Nektar is a clinical-stage biotech rebuilding around rezpegaldesleukin, now advancing the drug into Phase 3 autoimmune-disease trials after earlier development setbacks. The verdict adds a potentially meaningful source of non-dilutive funding. A jury found Lilly breached the implied covenant of good faith and fair dealing and awarded Nektar $90 million plus interest. That is material for a company still funding late-stage clinical development, but it is not yet cash in the bank.

The headline win is tempered by legal uncertainty. The award remains subject to post-trial proceedings, and any judgment could be appealed. 〔0〕 The filing also gives no timing for a final judgment, interest calculation, payment, or appellate resolution, so the immediate business impact is better financial optionality—not a confirmed balance-sheet improvement.

This changes the funding backdrop more than the drug-development story. Rezpegaldesleukin's Phase 3 path was already underway before the verdict; the ruling does not provide new clinical evidence, alter trial plans, or remove the core risk that the program still depends on successful future studies. With no published consensus benchmark for this litigation outcome, the award is a genuine positive surprise versus the pre-verdict uncertainty, but its value should be discounted until the judgment survives post-trial review and appeal risk.

Bottom line: The verdict improves Nektar’s potential funding position and is the most important new event in this filing, but it is a contingent legal asset—not realized cash or a change to the clinical thesis.